What is AccuBoost?
AccuBoost operates at the intersection of medical technology and oncology, providing a sophisticated, non-invasive, real-time image-guided brachytherapy solution. Specifically engineered for patients diagnosed with stage 1 and stage 2 breast cancer, the platform offers a streamlined alternative to traditional radiation protocols following a lumpectomy. By enabling treatment completion in as few as 5 to 10 days, the technology significantly reduces radiation exposure to critical organs such as the heart and lungs. This precision-focused approach not only enhances patient comfort but also aligns with the broader industry shift toward personalized, high-efficacy cancer care. Trusted by leading cancer centers, AccuBoost continues to redefine the standard of care for post-surgical breast cancer management.
How much funding has AccuBoost raised?
AccuBoost has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in AccuBoost
PPP
Public-Private Partnership
What's next for AccuBoost?
With the successful closure of this late-stage financing, AccuBoost is poised to scale its operational infrastructure and expand its clinical adoption across major healthcare networks. The strategic focus will likely shift toward enhancing the accessibility of its proprietary brachytherapy technology, potentially through increased investment in clinical research and provider training programs. As the company matures, the emphasis will remain on optimizing patient outcomes and demonstrating long-term clinical superiority in the breast cancer treatment sector. This capital deployment serves as a critical catalyst for the firm to transition from a specialized innovator to a foundational player in the global oncology market, ensuring that its image-guided solutions become a standard component of the post-lumpectomy care continuum.
See full AccuBoost company page
